IMP321 and weekly paclitaxel as first-line chemoimmunotherapy for metastatic breast cancer (MBC)

Triebel, Frédéric; Brignone, Chrystelle; Grygar, Caroline; Marcu, Manon; Gutierez, M.

doi:10.1200/jco.2008.26.15_suppl.1045

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IMP321 is a novel immunomodulator derived from the natural human protein LAG-3, a ligand for MHC class II molecules which acts indirectly on T cell responses by MHC class II APC activation. [ 63 ] It was evaluated in combination with weekly paclitaxel in a phase I study in MBC at ASCO 2008 and was found to be well tolerated when given subcutaneously over 6 months.…”

Section: Future Therapiesmentioning

confidence: 99%

Novel therapies in breast cancer: what is new from ASCO 2008

Chu

2008

J Hematol Oncol

View full text Add to dashboard Cite

Introduction: Breast cancer is the most common female cancer and the second most common cause of female cancer-related deaths in the United States. World-wide, more than one million women will be diagnosed with breast cancer annually. In 2007, more than 175,000 women were diagnosed with breast cancer in the United States. However, deaths due to breast cancer have decreased in the recent years in part because of improved screening techniques, surgical interventions, understanding of the pathogenesis of the disease, and utilization of traditional chemotherapies in a more efficacious manner. One of the more exciting areas of improvement in the treatment of breast cancer is the entrance of novel therapies now available to oncologists. In the field of cancer therapeutics, the area of targeted and biologic therapies has been progressing at a rapid rate, particularly in the treatment of breast cancer.

show abstract

Section: Future Therapiesmentioning

confidence: 99%